Neurizon Therapeutics Limited, a clinical-stage biotech company dedicated to advancing innovative treatments for ...

PTC Therapeutics, Inc.’s PTCT share price has surged by 6.72%, which has investors questioning if this is right time to sell.

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 5.89%, which has investors questioning if this is right time to ...

The number of people who have the gene that causes Huntington's disease in Northern Scotland has been accurately counted for ...

AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.

Qure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...

The rate in the area is 14.5 per 100,000 people, more than five times the estimated worldwide rate of 2.71 per 100,000 people ...

Shawn Kortes, known for his philanthropic work in the community, started dialysis this year and is searching for a kidney ...

Areas of Scotland have the highest rates of Huntington’s disease in the world - The neurodegenerative disease slowly damages ...

Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.